بلغاريا - البلغارية - БАБХ (Българска агенция по безопасност на храните)

ФАРМА ВЕТ ООД - Тилозин тартрат - прах за прилагане във вода за пиене - 40 000 000 iu (50 g) - птици, свине

بلغاريا - البلغارية - БАБХ (Българска агенция по безопасност на храните)

Биовет АД - Тилозин - инжекционен разтвор - 200 mg/ml - говеда, кози, кучета, овце, свине

بلغاريا - البلغارية - БАБХ (Българска агенция по безопасност на храните)

Биовет АД - Тилозин (като tartarate) - прах за прилагане във вода за пиене/мляко - 500 mg/g - пилета, прасета, пуйки, телета

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridine - Множествена склероза - Други лекарства в нервната система - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

teva gmbh - диметил фумарат - multiple sclerosis, relapsing-remitting; multiple sclerosis - Имуносупресори - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

accord healthcare s.l.u. - диметил фумарат - multiple sclerosis, relapsing-remitting; multiple sclerosis - Имуносупресори - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Имуносупресори - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

sandoz gmbh - натализумаб - multiple sclerosis, relapsing-remitting; multiple sclerosis - Имуносупресори - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 и 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod хидрохлорид - multiple sclerosis, relapsing-remitting; colitis, ulcerative - Имуносупресори - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

الاتحاد الأوروبي - البلغارية - EMA (European Medicines Agency)

plusultra pharma gmbh - Сиролимус - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.